Date: 7 May 2013
Copyright:
Copyright B.Flannigan, R Samson & JD Miller (From Microorganisms in home and indoor work environments, Published by Taylor and Francis)
Notes:
Colonies on CYA 60 mm or more diam, usually covering the whole Petri dish, plane, velutinous, of low, usually subsurface, white mycelium, surmounted by a layer of closely packed, black conidial heads, ca 2-3 mm high; reverse usually pale, sometimes pale to bright yellow. Colonies on MEA varying from 30-60 mm diam, usually smaller than those on CYA and often quite sparse by comparison, otherwise similar. Colonies on G25N 18-30 mm diam, plane, velutinous, with white or pale yellow mycelium visible at the margins, otherwise similar to those on CYA; reverse pale or occasionally with areas of deep brown. No growth at 5°C. At 37°C, colonies 60 mm or more diam, covering the available space, sometimes sulcate, otherwise similar to those on CYA at 25°C.
Conidiophores borne from surface hyphae, 1.0-3.0 mm long, with heavy, hyaline, smooth walls; vesicles spherical, usually 50-75 µm diam, bearing closely packed metulae and phialides over the whole surface; metulae 10-15 µm long, or sometimes more; phialides 7-10 µm long; conidia spherical, 4-5 µm diam, brown, with walls conspicuously roughened or sometimes striate, borne in large, radiate heads.
Distinctive features
One of the best known of all fungal species, Aspergillus niger is distinguished by its spherical black conidia, derived from colonies which show little or no other colouring.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
